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Introduction
Prostate cancer (PCa) is the most frequently diagnosed cancer 
in men in Switzerland. Approximately 6,000 new PCa cases are di-
agnosed each year in Switzerland, of which about 1,000 are regis-
tered in the Canton of Zurich [1]. In the last decades, the number 
of incident cases has increased in Switzerland. One reason is the 
introduction of the PSA (prostate-specific antigen) test, which 
leads to a higher number of men being diagnosed with PCa at an 
early stage. A number of these tumors would remain undetected 
without the PSA test or would be detected at later stages [2]. It has 
been shown that only 3% of men diagnosed with PCa die of the 
disease, and only 16% of men having localized PCa benefit from 
treatments such as surgery or radiotherapy [3]. Many patients suf-
fer from severe adverse effects of treatment such as incontinence or 
impotence after surgery. In fact, recommendations state that only 
patients with a life expectancy of more than 10 years should be 
treated, whereas patients with localized PCa with a life expectancy 
shorter than 10 years should be placed under watchful waiting 
(WW) only [4, 5]. Current guidelines recommend, in addition to 
WW, active surveillance (AS) as a suitable treatment for low-risk 
patients with a long life expectancy [6, 7]. The estimation of the 
long-term relative survival (RS) of PCa patients compared to the 
general population based on factors such as age, treatment, stage, 
and grade helps to provide information regarding the suitability of 
different treatments for patients and, thus, to avoid over-treatment 
and preserve quality of life. Ladjevardi et al. [8] evaluated the RS of 
PCa patients in relation to Gleason score and treatment using data 
of Sweden’s National Prostate Cancer Registry. However, to our 
knowledge, only few studies investigated the association of age, 
stage, and grade with treatment choices compared to the recom-
mendations of published guidelines and estimated RS rates of PCa 
patients with respect to primary treatment. Furthermore, the inclu-
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Summary
Background: The aim of this study was to assess associa-
tions of stage, grade, and age with the primary treatment 
of prostate cancer (PCa) patients comparing the incidence 
years 2000/2001 and 2012/2013, and to estimate the rela-
tive survival (RS) for patients diagnosed in 2000/2001. 
Methods: We included 1,541 men diagnosed in 2000/2001 
and 1,605 men diagnosed in 2012/2013. Multiple imputa-
tion methods were applied to missing data for stage and 
grade. Multinomial logistic regression analyses were 
used to explore the associations of stage, grade, and age 
with treatment. RS was estimated using the Ederer II ap-
proach. Results: In 2000/2001, older patients were more 
likely to choose active surveillance (AS)/watchful waiting 
(WW) or to receive androgen deprivation therapy (ADT) 
compared to surgery; in 2012/2013, this association was 
only observed for ADT but not for AS/WW. In 2000/2001, 
the overall 1-, 5-, and 10-year RS was approximately 99, 
94, and 92%, respectively. RS was highest for patients 
who underwent surgical procedures or radiotherapy and 
considerably lower for patients with ADT. Conclusion: 
Our data show that today AS/WW is an option not only 
for patients with a life expectancy of < 10 years but also 
for younger men with localized PCa. PCa patients have a 
good RS if the cancer is diagnosed at an early stage. 
© 2017 S. Karger GmbH, Freiburg
Received: November 24, 2016
Accepted: April 27, 2017
Published online: August 17, 2017
Katarina Luise Matthes
Cancer Registry Zurich and Zug
University Hospital Zurich
Vogelsangstrasse 10, 8091 Zurich, Switzerland
katarinaluise.matthes@usz.ch
© 2017 S. Karger GmbH, Freiburg
S. Dehler current address: Abteilung Gesundheit, Kantonsärztlicher Dienst, Bachstrasse 
15, 5001 Aarau, Switzerland
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
89
.2
06
.1
16
.9
1 
- 1
2/
28
/2
01
7 
5:
33
:3
6 
PM
Treatment Choice and Relative Survival of 
Prostate Cancer Patients
Oncol Res Treat 2017;40:484–489 485
sion of 2 time periods more than 10 years apart provides insight 
into changes in treatment choices over time based on age, stage, 
and grade. The aim of this study was to assess the associations of 
stage, grade, and age with the primary treatment of PCa patients in 
the Canton of Zurich, Switzerland comparing the incidence years 
2000/2001 and 2012/2013, and to estimate RS based on these fac-
tors for patients diagnosed in 2000/2001.
Materials and Methods
Study Population
The epidemiological Cancer Registry Zurich and Zug is the largest in Swit-
zerland covering roughly 1.6 million inhabitants. The Registry was established 
in 1980 to register every cancer patient in the canton of Zurich (and since 2011 
in the canton of Zug). The Registry is almost complete; the percentage of death 
certificate only (DCO) cases is 1.9% for the period of 1988–2012, and the per-
centage of morphologically verified cases is 93.2% [9]. We included PCa pa-
tients who lived in the Canton of Zurich at the time of diagnosis. PCa was de-
fined based on the ICD-10 coding (International Statistical Classification of 
Diseases and Related Health Problems). To compare former and current treat-
ment choices, we extracted the data of men diagnosed in the years 2000/2001 
and 2012/2013. We restricted our data to patients with PCa as the first primary 
cancer diagnosis and excluded DCO cases and cases diagnosed at autopsy. Of 
1,667 PCa cases in 2000/2001, we excluded 78 DCO cases (4.7%) and 48 cases 
that were diagnosed at autopsy (2.9%). In 2012/2013, of 1,750 PCa cases, 14 
DCO cases (0.8%) and 131 cases diagnosed at autopsy (7.5%) were excluded. 
Hence, for 2000/2001 we finally included 1,541 and for 2012/2013 1,605 PCa 
patients. We obtained data pertaining to the patients’ vital status from the Citi-
zen Services Departments in the Canton of Zurich. Patients diagnosed in 
2000/2001 were followed until death or for a maximum of 10 years after diag-
nosis, whichever came first. The Registry systematically registers the type of 
cancer, name, date of birth, sex, place of residence, stage and grade of the 
tumor, and information regarding treatment. The stage of the tumor was classi-
fied based on the TNM classification. We restricted the TNM classification to 
the T-classification, hereafter called stage, which describes the tumor extent. 
The pathological stage was used if available; otherwise the clinical stage was 
used. In many cases, we only had knowledge about the tumor grade but not the 
corresponding Gleason score; hence, the PCa tumor grade was used. Only the 
primary treatment of a patient was considered. We distinguished between sur-
gical procedures, radiotherapy, and androgen deprivation therapy (ADT). As 
we cannot directly distinguish between AS and WW, we defined 1 treatment 
group for AS/WW. Age was divided into 4 groups (< 60, 60–69, 70–79, and > 79 
years). 
Statistical Methods
In order to handle missing values for stage and grade, multiple imputation 
with chained equations (MICE) was applied to impute the incomplete data [10, 
11]. The imputation model includes the incomplete variables stage and grade 
and the complete variables date of diagnosis, age at diagnosis, survival time, 
vital status, and primary treatment. The missing variables were imputed using a 
multinomial logit model. Since the fraction of missing stage information in the 
years 2000/2001 and 2012/2013 was approximately 15 and 5%, respectively, and 
missing grade information was 7% in both periods, we created 20 complete 
datasets. For each dataset, the analyses were performed separately and merged 
afterwards using Rubin’s rule [12]. After imputation, we tested for a trend in 
treatment choices by age, stage, and grade using a chi-squared test for trends in 
proportions. Multinomial logistic regression analyses were used to assess the 
associations of stage, grade, and age with treatment choices.
For the diagnosis years 2000/2001, we performed RS analyses. RS is defined 
as the ratio of the observed and the expected survival. The expected survival was 
estimated from a comparable general population using the Ederer II approach 
[13] with a life table for the Canton of Zurich [14]. Mortality rates in the Can-
ton of Zurich for each year were available in 22 age groups. To interpolate the 
abridged life table, the Elandt-Johnson method was applied [15]. Stratified anal-
yses were conducted by age groups, stage, grade, and primary treatment. All 
statistical analyses were performed in R (version 3.2.2). The R package ‘MICE’ 
[16] was used to impute the missing data, the package ‘nnet’ [17] to perform the 
regression models, and the package ‘relsurv’ [18] to estimate RS rates. 
Results
The mean age at diagnosis of men diagnosed in 2000/2001 was 
70.1 years (standard deviation (SD) = 9.0, median = 70.0, inter-
quartile range = 12.0). During the follow-up period of 10 years, 833 
(54%) of 1,541 men died and 27 (1.8%) were lost to follow-up. The 
average length of follow-up was 7.7 years (SD = 3.2, median = 9.9, 
interquartile range = 4.6). For the diagnosis years 2012/2013, the 
mean age at diagnosis was 69.8 years (SD = 9.7, median = 69.0, in-
terquartile range = 12.0).
Table 1 shows the age and tumor characteristics of the patients 
diagnosed in 2000/2001 and 2012/2013 after multiple imputations 
stratified by primary treatments. Comparing the years of diagnosis, 
the proportion of patients undergoing surgery was slightly higher 
in 2012/2013, whereas the proportion of men with radiotherapy 
decreased from 11% in 2000/2001 to 3% in 2012/2013. The propor-
tions of ADT and AS/WW were similar in both periods. Stratified 
by stage, the proportion of men with a T1 tumor was lower in 
2000/2001 (28%) than in 2012/2013 (49%), while the proportion of 
men with a T2 tumor was higher in 2000/2001 (51%) than in 
2012/2013 (35%). The proportion of men younger than 60 years of 
age under AS/WW was 17% in 2000/2001 and 29% in 2012/2013, 
while the proportion of men older than 79 years of age under AS/
WW was 45% in 2000/2001 and 35% in 2012/2013. In 2012/2013, 
ADT was more frequent for higher-stage tumors (37%) compared 
to 2000/2001 (16%).
Table 2 presents the associations of age, stage, and grade with 
treatment choices using the imputed dataset for patients diagnosed 
in 2000/2001 and 2012/2013. All results were adjusted for age, 
grade, and stage. In 2000/2001, age was associated with treatment 
choices indicating that older patients were less likely to have sur-
gery. In addition, AS/WW was more likely a treatment choice for 
older patients and patients with an early-stage tumor. Further-
more, higher tumor grade was associated with higher odds of re-
ceiving ADT compared to surgery. Interestingly, in 2012/2013, age 
was not associated with treatment choice anymore except for ADT 
(higher age associated with higher odds of ADT versus surgery). In 
2000/2001, there was no association between PCa stage and active 
treatment, but in 2012/2013, having a stage T4 versus T1 tumor 
was significantly associated with ADT versus surgery.
Figure 1 illustrates the RS of patients diagnosed in 2000/2001 
using the imputed data stratified by age, stage, grade, and primary 
treatment. Overall, the 1-, 5-, and 10-year RS was 98.5% (95% con-
fidence interval (CI) 97.3–99.6), 93.8% (95% CI 91.2–96.4), and 
91.7% (95% CI 87.8–95.7), respectively. The RS of men younger 
than 80 years was close to 100%, whereas men aged 80 years and 
older had a lower RS. RS was highest for men diagnosed with a T1 
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and T2 tumor but lower for patients with a T3 and especially for 
those with a T4 tumor. Stratification by tumor grade shows that RS 
increased over time for men with a grade 1 tumor and that 5- and 
10-year RS rates were higher than 100%. However, the RS of men 
diagnosed with a grade 3/4 tumor decreased from 94.5% (95% CI 
91.0–98.0) after 1 year to 59.6% (95% CI 46.4–72.8) after 10 years. 
Stratification by primary treatment choices revealed that the RS of 
patients who underwent surgical procedures or radiotherapy was 
approximately 100% within 10 years, whereas the RS of patients 
who underwent ADT was considerably lower. The RS of men 
under AS/WW decreased over time. 
Discussion
In this study among PCa patients of a Swiss cancer registry, we 
observed associations of age, stage, and grade with treatment 
choices. In general, older-aged patients were more likely to receive 
ADT or AS/WW versus surgery than younger patients, and men 
with a T1 tumor were more likely to be under AS compared to men 
with a higher-stage tumor. Additionally, we noted a shift in the as-
sociation of age with treatment choices such that in 2000/2001, pa-
tients older than 70 years were significantly more likely to undergo 
radiotherapy or to be under AS/WW compared to surgery, which 
we did not observe in 2012/2013 (table 2). Furthermore, the earlier 
PCa is diagnosed, the higher the RS for patients. RS was highest for 
patients treated with surgery or radiotherapy and considerably 
lower for patients undergoing ADT. 
These findings are in line with former and current guidelines. 
The 2001 guideline of the European Association of Urology (EAU) 
[4] and the 2003 guideline of the European Society for Medical On-
cology (ESMO) [5] recommended surgery and radiotherapy for 
men with localized PCa who were younger than 70 years of age, 
whereas AS/WW was recommended for men with localized PCa 
over 70 years old. For men with advanced disease and for unfit pa-
tients, ADT is a treatment option. Our results reflect these former 
recommendations, illustrating that surgery was more frequent in 
men younger than 70 years and AS/WW was an option for men 
older than 70 years. Comparing the former guidelines with the cur-
rent EAU guideline from 2013 [7] and the EMSO guideline from 
2015 [6], a major change is the recommendation of AS also for pa-
tients with localized PCa who have a life expectancy of more than 
10 years. Indeed, the number of men under AS/WW in the younger 
age groups increased remarkably in our study. Our results show 
that treatment decisions depend on age; however, in addition, they 
should also depend on life expectancy, which we cannot reflect in 
our study. Furthermore, we observed that ADT was more fre-
quently a treatment option for advanced-stage and undifferenti-
ated tumors. Between 2000/2001 and 2012/2013, the number of 
men with a T4 tumor treated with ADT increased from 16 to 37%. 
We observed a stage migration from T2 to T1 tumors from 
2000/2001 to 2012/2013. This reflects the growing use of PSA 
screening in Switzerland [19], which leads to a higher proportion 
of men having a T1 tumor. We hypothesize that, despite the debate 
about the benefits of PSA screening, men are more aware of PCa 
and still perform opportunistic testing.
A study from the Munich Cancer Registry in Germany covering 
the years 1990–2010 reported an increase in men undergoing sur-
gery from 45% in 2000–2004 to 53% in 2005–2010 [20]. Our results 
confirm the increasing use of surgery, although the proportions in 
our study are slightly higher. We speculate that the robot-assisted 
da Vinci surgical system, first introduced in 2000 [21], could have 
Table 2. Association of primary treatment with age, stage, and grade
  Radiotherapy vs. surgerya   ADT vs. surgerya   AS/WW vs. surgerya
  2000/2001   2012/2013b   2000/2001   2012/2013b   2000/2001   2012/2013b
  OR 95% CI   OR 95% CI   OR 95% CI   OR 95% CI   OR 95% CI   OR 95% CI
Age, years                                  
< 60a 1.00     1.00     1.00     1.00     1.00     1.00  
60–69 1.23 0.71–2.15   0.90 0.36–2.25   1.70 0.78–3.70   1.01 0.44–2.36   1.02 0.64–1.62   0.88 0.59–1.32
70–79 2.18 1.25–3.80   0.85 0.32–2.20   2.80 1.28–6.09   2.69 1.20–6.01   2.90 1.86–4.50   0.83 0.55–1.27
> 79 0.21 0.06–0.75   0.38 0.10–1.44   3.92 1.69–9.09   5.02 2.18–11.6   3.65 2.21–6.02   1.00 0.63–1.62
Stage                                  
T1a 1.00     1.00     1.00     1.00     1.00     1.00  
T2 1.04 0.61–1.77   0.35 0.16–0.78   0.91 0.49–1.68   0.57 0.32–1.01   0.49 0.35–0.68   0.09 0.07–0.13
T3 1.42 0.74–2.72   0.81 0.36–1.83   1.72 0.86–3.45   1.68 0.99–2.83   0.60 0.39–0.93   0.10 0.06–0.17
T4 2.19 0.87–5.44   2.93 0.56–15.3   1.45 0.51–4.11   4.69 1.89–11.6   0.57 0.27–1.22   0.84 0.34–2.03
Grade                                  
1a 1.00     – –   1.00     – –   1.00     – –
2 1.87 1.11–3.13   – –   2.52 1.09–5.80   – –   1.21 0.87–1.71   – –
3/4 1.75 0.95–3.22   – –   6.05 2.57–14.2   – –   1.44 0.96–2.16   – –
aSurgery, age < 60, stage T1, and grade 1 are the references.
bFor the diagnosis years 2012/2013, the results are also adjusted for grade, but due to the small number of cases for grade 1, results are not presented.
CI = Confidence interval; OR = odds ratio; ADT = androgen deprivation therapy; AS/WW = active surveillance/watchful waiting.
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an impact on the increasing number of surgeries. The proportion 
of men who underwent ADT was much higher in Germany, 
namely 29% in 2000–2004 and 21% in 2005–2010, while the pro-
portion remained constant at 9% in the Canton of Zurich. How-
ever, in the Munich Cancer Registry, the number of men under 
AS/WW was around 20% in both periods, whereas we observed 
about 28% in the Canton of Zurich. 
Evaluating the RS of PCa patients in Germany revealed an over-
all 10-year RS of 91% [22, 23], and studies based on US SEER data 
observed a 10-year RS of PCa patients between 95 and 100% [23, 
24]. The RS in our study is comparable with that observed in Ger-
many, but is lower than in the US. Different incidence and stage 
distributions in the US and Germany may partly explain these dif-
ferences [23]. In the US, PSA screening was used more frequently 
and introduced earlier compared with Switzerland or Germany. 
An earlier detection due to PSA screening and over-diagnosis of 
asymptomatic PCa postpone the time of death and may result in a 
longer survival time (lead-time bias) [25]. 
The results of this study are in line with previous studies from 
the US and the UK that also reported highest RS for men 60–74 
years old [24, 26] (fig.  1A). This observation might be explained 
the fact that more men in their 60s or 70s had a PSA test [26].
Several German, US, and UK studies observed that the RS of 
men with localized PCa was higher than 100% and increased over 
time [22, 24, 26]. We also observed an RS of about 100% for men 
with a T1 or T2 tumor (fig. 1B) and an RS of over 100% for men 
with grade 1 tumors (fig. 1C). These high RS rates probably indi-
cate a selection bias [22]. Firstly, PSA screening tends to be used 
more often by men with a more health-conscious behavior, which 
implies that men having an early-stage PCa are generally healthier 
than men of the general population [27]. Secondly, men diagnosed 
with an early-stage tumor might improve their lifestyle as conse-
quence of this diagnosis, e.g. quit smoking, engage in physical ac-
tivity more frequently, or change their diet [28]. A third reason 
could be the influence of the socioeconomic status of the patients. 
Liu et al. [29] reported that a high socioeconomic status was associ-
ated with higher odds of performing a PSA test. Rapiti et al. [30] 
reported similar results for Geneva, Switzerland. 
The low RS of men receiving ADT (fig. 1D) is likely explained 
by the more frequent ADT use in older men or in men with ad-
vanced-stage PCa. Furthermore, ADT could lead to side effects 
that are related to a higher risk of all-cause mortality [31].
A strength of this study is the almost complete coverage of PCa 
patients in the Canton of Zurich. Furthermore, we had almost 
complete vital status information for the patients diagnosed in 
2000/2001 to estimate RS. Another strength is the inclusion of 2 
time periods (2000/2001 and 2012/2013) which allows for assessing 
changes in treatment choices over time. However, this study also 
has some limitations. The grading was not comparable between the 
periods 2000/2001 and 2012/2013 because in 2005, the original 
Gleason grading [32] was modified. Gleason score 2–4 (grade 1) 
should not have been assigned anymore because this diagnosis is 
poorly reproducible even for experts; in addition, a Gleason score 2 
may today be referred to as adenosis, not as PCa. Consequently, 
grade 1 tumors diagnosed in the years 2000 and 2001 would possi-
bly receive a higher grading today [33]. Furthermore, our treat-
ment information is limited so that we cannot clearly distinguish 
between AS or WW. In addition, we only have information about 
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radiotherapy and cannot further subdivide into external beam ra-
diation therapy and brachytherapy. Moreover, we investigated only 
the first primary treatment. Treatment combinations, neoadjuvant, 
adjuvant, or postoperative therapies were not reflected in our 
study. We could also not consider delayed treatments after AS/
WW. Furthermore, the presence of other chronic diseases at the 
time of diagnosis may affect the treatment choices. Unfortunately, 
we do not have information on co-morbidities of the PCa patients.
Conclusion
In conclusion, our study showed an association of age, stage, 
and grade with treatment choices as recommended in official 
guidelines. We illustrated that today AS/WW is not only an option 
for patients with a life expectancy shorter than 10 years but also for 
younger men having localized PCa. An increase in AS/WW might 
help to counteract over-treatment especially of younger patients 
and those with early-stage PCa. Our findings are consistent with 
results from previous studies stating that PCa patients have a good 
RS if the cancer is diagnosed at an early stage. An RS above 100% 
probably indicates a selection bias due to PSA screening, which 
tends to be more often used by men with a more health-conscious 
behavior.
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